INTRODUCTION
Haploidentical stem cell transplantation (HSCT) offers the benefits of rapid and nearly universal donor availability and has been accepted worldwide as an alternative treatment for patients with hematologic malignancies who do not have a completely HLAmatched sibling or who require urgent transplantation. [1] [2] [3] [4] Over the past decade, we established a unmanipulated haploidentical blood and marrow transplantation protocol (HBMT). 1, 3 Long follow-up showed that the probabilities of overall survival (OS) and leukemia-free survival (LFS) at 3 years were 67% and 63%, respectively, in patients who underwent unmanipulated HBMT, 4 which were comparable with those who received HLA-identical sibling transplantation or HLA-matched unrelated donor transplantation. 1 Patients receiving unmanipulated HBMT can achieve desirable health-related quality of life (HRQoL). 5 Recent years, several work had been conducted on devising novel strategies to improve clinical outcomes of unmanipulated HBMT. Those strategies include investigating optimal dose of antithymocyte globulin (ATG) 6 , selecting the best donor 7 and modified donor lymphocyte infusion (mDLI) to reduce relapse following unmanipulated HBMT. [8] [9] [10] Here, we summarize the recent advances in unmanipulated HBMT settings, focusing on the strategies that contribute to improving transplant outcomes.
OUTCOMES OF UNMANIPULATED HBMT: AN UPDATE
Based on immune tolerance induced by G-CSF and ATG, 11 researchers from Peking University established a unmanipulated HBMT protocol. 3, 4 Over the past 9 years, 756 patients with leukemia underwent haploidentical transplantation using this protocol, which combines G-CSF-primed bone marrow and PBSCs without in vitro T-cell depletion. Of these patients, 752 (99%) achieved sustained, full donor chimerism. The incidence of grades III-IV acute GvHD was 14%, which was comparable to those reported by Bashey et al. 12 and Castagna et al. 13 The 2-year cumulative incidence of total chronic GvHD was 53%. The 2-year cumulative incidences of relapse were 15% and 26% in the standard-risk and high-risk groups, respectively. The 3-year cumulative incidence of transplantation-related mortality was 18%. After a median follow-up of 1154 days (range: 335-3511 days), 480 patients survived with the 3-year LFS rates of 68% and 49% in the standard-risk and high-risk groups, respectively. 4 Impressively, lower LFS was associated with highrisk disease status, chronic myelogenous leukemia disease type, neutrophil engraftment beyond 13 days and the occurrence of grades II-IV acute GvHD. Our data showed that aplastic anemia patients who received allografts from haploidentical donors could achieve promising outcomes. The OS was 64.6 ± 12.4% with a median 746-day (90-1970) follow-up for surviving patients. 14 The first 90 days after unmanipulated HBMT are characterized by persistent CD4 + and CD4 + naive T cell, B cell lymphopenia. 15, 16 However, compensatory expansion of monocytes, cytokineproducing CD56 bright natural killer cells and cytotoxic T cells with the central memory CD45RO
+ CD62L + cell phenotype may partly prevent leukemia relapse and infections. Regarding the reconstitution of T-cell function, one interesting finding is that the ability of T cells to secrete interferon-γ and interleukin-4 recovers to normal level by day 30 after transplantation in patients without acute GvHD following unmanipulated HBMT, 16 although de novo thymic production should be explored further.
Little is known about HRQoL after HSCT. Retrospective data from our center showed that patients receiving unmanipulated HBMT had higher scores in physical functioning, general health, body pain, vitality and emotional role functioning, and these patients functioned significantly better on the physical and mental component summaries. Long-term survivors exhibited better HRQoL. Importantly, extensive chronic GvHD had a strong, negative impact on patient HRQoL, whereas male sex, lower age when receiving transplant, and returning to work or school were associated with positive impacts on at least one subscale. Given the negative effect of extensive chronic GvHD on HRQoL, this should be successfully controlled and treated to improve outcomes in patients after HBMT. 5 Furthermore, a prospective, multicenter and large-scale study is warranted to confirm our results.
Latter effect is another major concern after allogeneic transplantation. We found that the 5-year cumulative incidence of at least one late effect and multiple late effects was 47.30 ± 0.17% versus 58.21 ± 0.16% (P = 0.134) and 17.97 ± 0.10% versus 34.28 ± 0.15% (P = 0.001) for unmanipulated HBMT recipients versus identical sibling donor transplant recipients, respectively. 17 The cumulative incidence of keratoconjunctivitis sicca, periodontitis, ankylosis, myalgia and nephrotic syndrome was lower among unmanipulated HBMT recipients compared with identical sibling donor transplant recipients. Severe chronic GvHD, multiple pre-HSCT chemotherapy cycles, female donor and older age were risk factors for at least one late effect. Female donor, older age and long-term immunosuppressive therapy were associated with multiple late effects. 17 These data suggests that unmanipulated HBMT recipients have a lower risk of late effects compared with identical sibling donor transplant recipients, possibly due to differences in protocols for GvHD prophylaxis, and long-term follow-up after transplantation is recommended.
More recently, we reported the clinical outcome of 410 consecutive children who received either single umbilical cord blood transplantation (UCBT, n = 37) or unmanipulated HBMT (n = 373) during the same time period. For each UCBT recipient, three recipients matched for year of SCT, underlying diseases, disease status and the length of follow-up were randomly selected from the HBMT cohort. Hematopoietic recovery was significantly faster in HBMT recipients than in UCBT recipients. The incidence of chronic GvHD was significantly higher in HBMT recipients. The incidence of CMV-related interstitial pneumonia was higher in UCBT recipients. The HBMT recipients had better 1-year OS (73.0% versus 56.8%, P = 0.048), lower 1-year (18.0% versus 35.1%, P = 0.026) and 2-year TRM rates (19.9% versus 35.1%, P = 0.044). The relapse and LFS rates did not differ significantly between the groups. Our results showed that compared with UCBT, unmanipulated HBMT can improve the outcomes of pediatric hematologic malignancies. 18 The unmanipulated HBMT protocol was also extended a post-remission treatment for AML patients with unfavorable cytogenetics in CR1. 3 Among 419 newly diagnosed AML patients, 132 cases with unfavorable cytogenetics achieved CR1. Of the 132 patients, 74 patients received chemotherapy alone and 58 patients received HSCT as the post-remission treatment. The cumulative incidence of relapse (CIR) at 4 years was 37.5%. The OS and disease-free survival (DFS) rates at 4 years were 64.5% and 55.6%, respectively. The HBMT group CIR was significantly lower than that of the chemotherapy group (12.0% versus 57.8%; Po 0.0001). HBMT resulted in superior survival compared with chemotherapy alone (4-year DFS, 73.1% versus 44.2%, respectively; P o 0.0001; 4-year OS, 77.5% versus 54.7%, respectively; P = 0.001). Multivariate analysis revealed post-remission treatment (HBMT versus chemotherapy) as an independent risk factor affecting relapse, DFS and OS. 3 These observations, for the first time, suggest that haploidentical HSCT should be included in the treatment algorithm, as a viable option for adults AML with unfavorable cytogenetics who lack a matched donor.
In summary, unmanipulated HBMT has been one of the most applied haploidentical transplant protocol with rapid immune recovery 16 and desirable HRQoL. 5 The risk of late effects after HBMT was lower than those of identical sibling donor transplant HSCT. 17 Unmanipulated HBMT shows superior in treating pediatric hematological malignancies compared with UCBT 18 and could be successfully used as a post-remission treatment algorithm for adults AML with unfavorable cytogenetics, 3 although improvements of this protocol are still needed in future.
STRATEGIES TO IMPROVE TRANSPLANT OUTCOMES FOLLOWING UNMANIPULATED HBMT
Many approaches have been developed or currently being designed to improve transplant outcomes of unmanipulated HBMT, such as investigating optimal dose of ATG, 6 selecting the best donor and mDLI to reduce relapse. 9 Here, we present only recent completed studies regarding improvement of clinical outcomes following unmanipulated HBMT.
Optimal dose of ATG in unmanipulated HBMT settings The use of ATG to induce immune tolerance is one of the most important basis of our haploidentical protocol. 11 However, the optimal dose of ATG remains unclear. In a recent randomized, clinical study, 224 patients with standard-risk hematological malignancy who underwent unmanipulated HBMT were enrolled. One hundred and twelve patients received 6 mg/kg ATG, and the remaining patients received 10 mg/kg ATG. The incidence of grade III-IV acute GvHD was higher in the ATG-6 group than in the ATG-10 group (16.1% versus 4.5%, P = 0.005). EBV reactivation occurred more frequently in the ATG-10 group than in the ATG-6 group (25.3% versus 9.6%, P = 0.001). The 1-year DFS rates were 84.3% and 86.0% for the ATG-6 group and ATG-10 groups, respectively (P = 0.88). These data indicate that, although 6 mg/kg ATG applied in our protocol decreased the risk of EBV reactivation compared with 10 mg/kg ATG, this treatment exposes patients to a higher risk for severe acute GvHD. 6 Therefore, further study is needed to investigate the optimal dose of ATG in unmanipulated haploidentical settings.
Selection of the best donor Haploidentical transplant recipients usually have more than one donors, this raises a issue that how can we choose the best donor before transplantation. Recently, we analyzed donor-recipient risk factors relevant to selection of optimal donor for HSCT. The results showed that: (1) male donor had lower incidence of GvHD, lower rate of NRM and higher probabilities of OS and LFS, compared with female donor. (2) Patients receiving allografts from donor younger than 30 years old had a superior transplant outcomes than those with donor older than 30 years old. (3) The rate of GvHD was not associated with the extent of HLA disparity or any individual allele disparity. (4) Father donor was better than mother donor. (5) Patients receiving non-inherited maternal antigenmismatched donor allografts have a lower incidence of II-IV acute GvHD. 7 These data suggested that, not abiding by the rule of HLA disparity, significant different outcomes were achieved among various haploidentical donors and proved once again that HSCT overcame HLA barriers. Instead of HLA disparity, donor age, the family relationship and non-inherited maternal antigen mismatch are important risk factors under our treatment modality. mDLI to decrease relapse after unmanipulated HBMT To decrease the relapse rate, we developed a mDLI protocol entailing infusion of donor G-CSF-mobilized PBSCs and short-term application of immunosuppressive agents after DLI for GvHD prophylaxis; this mDLI protocol has been successfully used for prophylaxis and treatment of relapse in patients with advanced leukemia receiving unmanipulated HBMT without compromising the GvL effects. 9, 19 Recently, we retrospectively analyzed data from 88 patients with advanced-stage acute leukemia after unmanipulated HBMT; patient treatment either did (n = 61) or did not (n = 27) include mDLI. The 2-year CIRs in patients receiving prophylactic mDLI and not receiving prophylactic mDLI were 36% and 55% (P = 0.017), respectively.
19 Estimated survival at 3 years was 31% for patients receiving prophylactic mDLI and 11% for patients not receiving prophylactic mDLI (P = 0.001). The 3-year probability of LFS was also higher in patients who received prophylactic mDLI (22%) compared with patients who did not (11%; P = 0.003). Multivariate analysis showed that higher OS was associated with use of prophylactic mDLI, AML and female sex, suggesting that use of prophylactic mDLI may increase the survival of patients with advanced-stage acute leukemia who receive HBMT. 19 On the basis of a previous observation of strong correlations between leukemia-associated aberrant immune phenotypes and WT1 and leukemia relapse, DFS, and survival in patients with acute leukemia receiving allotransplantation, 9 we prospectively studied the effects of risk stratification-directed interventions for minimal residual disease (MRD) on relapse and DFS in 814 subjects with standard-risk acute leukemia who received allo-HSCT in first or second CR. Patients with high-relapse rate in a total of 709 subjects were MRD − after transplantation (Group A); 105 subjects were MRD+, 49 received low-dose interleukin (IL-2, Group B) and 56 received mDLI with or without low-dose IL-2 (Group C). Post-transplantation immune suppression for GvHD was also modified based on MRD state. Group C showed significantly lower cumulative risk of relapse and higher DFS and OS than in subjects in Group B (P = 0.001 and P = 0.002, respectively), but did not differ from subjects in Group A. Multivariate analyses showed that MRD state and mDLI were significantly correlated with relapse and DFS. 8 These data provide new evidence about a possible exciting strategy to improve transplantation outcomes in patients with hematological malignancies, suggesting that risk stratificationdirected mDLI may reduce relapse and improve survival of subjects with standard-risk acute leukemia after HSCT. Overall, mDLI is a feasible strategy to decrease the incidence of relapse and improve transplant outcomes after unmanipulated HBMT.
FUTURE DIRECTIONS
Currently, nearly 50-70% patients who underwent unmanipulated HBMT can achieve long-term survival. However, several issues, including GvHD, poor graft function, delayed immune reconstitution and relapse, remain obstacles to improve transplant outcomes. Recently, we found that the impaired bone marrow microenvironment, especially deficiency of endothelial progenitor cells, may contribute to the occurrence of secondary poor graft function after allogeneic SCT. 20 Therefore, elucidation of the underlying mechanisms of above-mentioned transplant related complications may help us to establish novel strategies to decrease the incidence of GvHD, poor graft function and enhance the anti-leukemia effects as well as immune recovery. Currently, several clinical trials are ongoing in unmanipulated HBMT settings (http://ClinicalTrials.gov identifiers NCT01617473, 'Randomized Trial of Unmanipulated Mobilized Blood/Marrow Versus Blood Haploidentical Transplant With Standard-risk Leukemia' and NCT01857336 'Infusion of Recombinant Human Granulocyte Colony Stimulating Factor Mobilized Peripheral Harvest for Poor Engraftment After Hematopoietic Stem Cell Transplantation'), both of which may lead to the improvement of transplant outcomes.
